{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,10]],"date-time":"2026-01-10T23:39:07Z","timestamp":1768088347176,"version":"3.49.0"},"reference-count":17,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2017,1,22]],"date-time":"2017-01-22T00:00:00Z","timestamp":1485043200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"name":"U.S. Cancer Pain Relief Committee","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}]},{"DOI":"10.13039\/100007313","name":"University of Texas MD Anderson Cancer Center","doi-asserted-by":"publisher","award":["N\/A"],"award-info":[{"award-number":["N\/A"]}],"id":[{"id":"10.13039\/100007313","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Support Care Cancer"],"published-print":{"date-parts":[[2017,6]]},"DOI":"10.1007\/s00520-016-3553-z","type":"journal-article","created":{"date-parts":[[2017,1,22]],"date-time":"2017-01-22T01:42:12Z","timestamp":1485049332000},"page":"1809-1817","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":23,"title":["A predictive model of inflammatory markers and patient-reported symptoms for cachexia in newly diagnosed pancreatic cancer patients"],"prefix":"10.1007","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4063-189X","authenticated-orcid":false,"given":"David R.","family":"Fogelman","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"J.","family":"Morris","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Xiao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Hassan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Vadhan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"M.","family":"Overman","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"S.","family":"Javle","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Shroff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G.","family":"Varadhachary","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R.","family":"Wolff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L.","family":"Vence","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"A.","family":"Maitra","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"C.","family":"Cleeland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"X. S.","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2017,1,22]]},"reference":[{"issue":"1","key":"3553_CR1","doi-asserted-by":"publisher","first-page":"5","DOI":"10.3322\/caac.21254","volume":"65","author":"RL Siegel","year":"2015","unstructured":"Siegel RL, Miller KD, Jemal A et al (2015) Cancer statistics 2015. Ca Cancer J Clinicians 65(1):5\u201329","journal-title":"Ca Cancer J Clinicians"},{"issue":"5","key":"3553_CR2","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1016\/S1470-2045(10)70218-7","volume":"12","author":"K Fearon","year":"2011","unstructured":"Fearon K, Strasser F, Anker SD et al (2011) Definition and classification of cancer cachexia: an international consensus. Lancet Oncol 12(5):489\u2013495","journal-title":"Lancet Oncol"},{"issue":"34","key":"3553_CR3","doi-asserted-by":"publisher","first-page":"4039","DOI":"10.1200\/JCO.2015.61.4578","volume":"33","author":"H Hurwitz","year":"2015","unstructured":"Hurwitz H, Uppal N, Wagner SA et al (2015) Randomized, double blind, phase II study of ruxolitinib or placebo in combination with capecitabine in patients with metastatic pancreatic cancer for whom therapy with gemcitabine has failed. J Clin Oncol 33(34):4039\u20134047","journal-title":"J Clin Oncol"},{"key":"3553_CR4","doi-asserted-by":"publisher","first-page":"519","DOI":"10.1016\/S1470-2045(15)00558-6","volume":"17","author":"JS Temel","year":"2016","unstructured":"Temel JS, Abernethy AP, Currow DC et al (2016) Anamorelin in patients with non-small-cell lung cancer and cachexia (ROMANA 1 and ROMANA 2): results from two randomized, double-blind, phase 3 trials. Lancet Oncol 17:519\u2013531","journal-title":"Lancet Oncol"},{"issue":"7","key":"3553_CR5","doi-asserted-by":"publisher","first-page":"1634","DOI":"10.1002\/1097-0142(20001001)89:7<1634::AID-CNCR29>3.0.CO;2-V","volume":"89","author":"CS Cleeland","year":"2000","unstructured":"Cleeland CS, Mendoza TR, Wang XS et al (2000) Assessing symptom distress in cancer patients: the M.D. Anderson Symptom Inventory. Cancer 89(7):1634\u20131646","journal-title":"Cancer"},{"key":"3553_CR6","doi-asserted-by":"publisher","unstructured":"Wang XS, Williams LA, Eng C et al (2010) Validation and application of a module of the M.D. Anderson Symptom Inventory for measuring multiple symptoms in patients with the gastrointestinal cancer (the MDASI-GI). Cancer 116(8):2053\u201363","DOI":"10.1002\/cncr.24920"},{"issue":"2","key":"3553_CR7","doi-asserted-by":"publisher","first-page":"382","DOI":"10.1007\/s10637-013-0053-6","volume":"32","author":"S Cousin","year":"2014","unstructured":"Cousin S, Hollebecque A, Koscielny S (2014) Low skeletal muscle is associated with toxicity in patients included in phase I trials. Investig New Drugs 32(2):382\u2013387","journal-title":"Investig New Drugs"},{"issue":"5","key":"3553_CR8","doi-asserted-by":"publisher","first-page":"e37563","DOI":"10.1371\/journal.pone.0037563","volume":"7","author":"O Mir","year":"2012","unstructured":"Mir O, Coriat R, Blanchet B et al (2012) Sarcopenia predicts early dose-limiting toxicities and pharmacokinetics of sorafenib in patients with hepatocellular carcinoma. PLoS One 7(5):e37563","journal-title":"PLoS One"},{"issue":"2","key":"3553_CR9","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1016\/j.clnu.2003.07.001","volume":"23","author":"W Davidson","year":"2004","unstructured":"Davidson W, Ash S, Capra S et al (2004) Weight stabilization is associated with improved survival duration and quality of life in unresectable pancreatic cancer. Clin Nutr 23(2):239\u2013247","journal-title":"Clin Nutr"},{"issue":"6","key":"3553_CR10","doi-asserted-by":"publisher","first-page":"827","DOI":"10.1080\/01635581.2013.804580","volume":"65","author":"J Bachmann","year":"2013","unstructured":"Bachmann J, Buchler MW, Friess H, Martignoni ME (2013) Cachexia in patients with chronic pancreatitis and pancreatic cancer: impact on survival and outcome. Nutr Cancer 65(6):827\u2013833","journal-title":"Nutr Cancer"},{"issue":"4","key":"3553_CR11","doi-asserted-by":"publisher","first-page":"817","DOI":"10.3109\/10428194.2013.816421","volume":"55","author":"H Lanic","year":"2014","unstructured":"Lanic H, Kraut-Tauzia J, Modzelewski R et al (2014) Sarcopenia is an independent prognostic factor on elderly patients with diffuse large B-cell lymphoma treated with immunochemotherapy. Leuk Lymphoma 55(4):817\u2013823","journal-title":"Leuk Lymphoma"},{"issue":"2","key":"3553_CR12","doi-asserted-by":"publisher","first-page":"302","DOI":"10.1017\/S0007114512001067","volume":"109","author":"KM Di Sebastiano","year":"2013","unstructured":"Di Sebastiano KM, Yang L, Zbuk K et al (2013) Accelerated muscle and adipose tissue loss may predict survival in pancreatic cancer patients: the relationship with diabetes and anemia. Br J Nutr 109(2):302\u2013312","journal-title":"Br J Nutr"},{"issue":"7","key":"3553_CR13","doi-asserted-by":"publisher","first-page":"1509","DOI":"10.1007\/s00268-012-1581-5","volume":"36","author":"BS Miller","year":"2012","unstructured":"Miller BS, Ignatoski KM, Daignault S et al (2012) Worsening central sarcopenia and increasing intra-abdominal fat correlate with decreased survival in patients with adrenocortical carcinoma. World J Surg 36(7):1509\u20131516","journal-title":"World J Surg"},{"issue":"1","key":"3553_CR14","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1016\/j.pan.2014.11.006","volume":"15","author":"I Ozola Zalite","year":"2015","unstructured":"Ozola Zalite I, Zykus R, Francisco Gonzalez M et al (2015) Influence of cachexia and sarcopenia on survival in pancreatic ductal adenocarcinoma: a systemic review. Pancreatology 15(1):19\u201324","journal-title":"Pancreatology"},{"issue":"3 suppl 1","key":"3553_CR15","doi-asserted-by":"publisher","first-page":"S81","DOI":"10.1016\/j.surg.2012.05.028","volume":"152","author":"T Pausch","year":"2012","unstructured":"Pausch T, Hartwig W, Hinz U et al (2012) Cachexia but not obesity worsens the postoperative outcome after pancreatoduodenectomy in pancreatic cancer. Surgery 152(3 suppl 1):S81\u2013S88","journal-title":"Surgery"},{"issue":"3","key":"3553_CR16","doi-asserted-by":"publisher","first-page":"153","DOI":"10.1007\/s13539-011-0034-6","volume":"2","author":"JT Dalton","year":"2011","unstructured":"Dalton JT, Barnette KG, Bohl CE et al (2011) The selective androgen receptor modulator GTx-024 (enobosarm) improves lean body mass and physical function in healthy elderly men and postmenopausal women: results of a double-blind, placebo-controlled phase II trial. J Cachexia Sarcopenia Muscle 2(3):153\u2013161","journal-title":"J Cachexia Sarcopenia Muscle"},{"issue":"9","key":"3553_CR17","doi-asserted-by":"publisher","first-page":"799","DOI":"10.1056\/NEJMoa1110557","volume":"366","author":"S Verstovsek","year":"2012","unstructured":"Verstovsek S, Mesa RA, Gotlib J et al (2012) A double-blind, placebo-controlled trial of ruxolitinib for myelofibrosis. N Engl J Med 366(9):799\u2013807","journal-title":"N Engl J Med"}],"container-title":["Supportive Care in Cancer"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s00520-016-3553-z\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s00520-016-3553-z.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2017,4,24]],"date-time":"2017-04-24T05:01:47Z","timestamp":1493010107000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s00520-016-3553-z"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,1,22]]},"references-count":17,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2017,6]]}},"alternative-id":["3553"],"URL":"https:\/\/doi.org\/10.1007\/s00520-016-3553-z","relation":{},"ISSN":["0941-4355","1433-7339"],"issn-type":[{"value":"0941-4355","type":"print"},{"value":"1433-7339","type":"electronic"}],"subject":[],"published":{"date-parts":[[2017,1,22]]}}}